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on third and seventh postoperative days compared to the 
enoxaparin group.
Conclusion Both thromboprophylactic agents were found 
to have appropriate antithrombotic effects after Thr. how-
ever, dabigatran was associated with an increased incidence 
of prolonged serous wound discharge, which might cause 
longer hospitalization and might instigate the use of pro-
longed antibiotic prophylaxis.
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Introduction
patients undergoing total hip replacement (Thr) are at 
increased risk of venous thromboembolism [15, 26, 30]. 
Appropriate pharmacologic thromboprophylaxis can signif-
icantly reduce the risk of venous thromboembolism (VTe) 
after Thr. currently recommended pharmacological pro-
phylactic agents for these patients include low-molecular-
weight heparins (LMWhs), synthetic pentasaccharide, 
orally administered anti Xa agents, direct thrombin inhibi-
tors, low-dose unfractionated heparin (LDuh), acetylsali-
cylic acid and adjusted-dose vitamin K antagonists (VKAs) 
[2, 21, 24]. Aspirin and VKAs are widely used in North 
America for Thr [21], but are not the favoured therapy for 
thromboprophylaxis in europe [2, 35, 42]. LMWhs have 
been shown to be more effective than unfractionated hepa-
rin, aspirin and VKAs across orthopaedic surgical prophy-
laxis protocols [21, 24, 28, 35]. LMWhs have become the 
standard of chemical thromboprophylaxis, based on two 
decades of clinical experience and well-designed studies 
[42].
Abstract 
Background Orally administered chemical thrombo-
prophylactic agents for total hip replacement (Thr) have 
become popular in recent years. certain clinical trials sug-
gest that the efficacy and the risk of major bleeding after 
administration of direct thrombin inhibitor dabigatran etex-
ilate are equivalent to the clinical trial comparator, subcuta-
neous low-molecular-weight heparin enoxaparin. Our aim 
was to compare and evaluate the incidence of minor haem-
orrhagic and soft-tissue adverse effects of enoxaparin and 
dabigatran.
Materials and methods 122 patients who were treated 
by elective cemented primary Thr were enrolled in our 
quasi-randomised study. Two groups were formed accord-
ing to which perioperative thromboprophylactic agent was 
used: 61 patients in enoxaparin group versus 61 patients in 
dabigatran group. Thigh volume changes, calculated perio-
perative blood loss, area of haematoma, wound bleeding, 
duration of wound discharge and intensity of serous wound 
discharge on postoperative day 3 and day 7 were recorded.
Results The duration and intensity of serous wound dis-
charge differed significantly between the two groups. Dura-
tion of wound discharge after drain removal was 2.2 (±2.7) 
days in the dabigatran group and 1.2 (±1.9) days in the 
enoxaparin group (p < 0.05). Significant increase in serous 
discharge was found in the dabigatran group (p < 0.05) 
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In europe, the direct thrombin inhibitor dabigatran 
etexilate, anti Xa agents apixaban and rivaroxaban are 
now approved for hip and knee arthroplasty as options for 
thromboprophylaxis [3, 4, 42]. The data suggests that the 
thromboprophylactic efficacies of these new agents are at 
least equivalent or potentially superior to the clinical trial 
comparator LMWh, enoxaparin. however, these new 
agents might be associated with a potentially higher bleed-
ing tendency [10, 12–14, 23, 38, 42]. recently, several 
reviews and trials focused on the potentially higher post-
operative bleeding and wound infection rate of rivaroxaban 
and dabigatran [22, 29].
clinical trials with dabigatran etexilate for Thr focused 
on major and clinically significant bleeding complica-
tions, as safety endpoints, with little attention paid to minor 
bleeding complications, and to surgical outcomes, such 
as wound healing, drainage, and surgical site infection 
[12–14].
Our aim was to compare the safety profile of enoxaparin 
and dabigatran etexilate in the use of primary Thr, with 
particular attention to minor haemorrhagic and soft-tissue 
adverse effects during the early postoperative period.
Materials and methods
We prospectively collected and reviewed all patients under-
going primary cemented Thr for osteoarthritis or avas-
cular necrosis of the femoral head from February 2011 to 
March 2012.
These patients were divided into two groups to receive 
either LMWh enoxaparin (clexane®, Sanofi-Aventis) 
(group 1) or the oral direct thrombin inhibitor dabigatran 
etexilate (pradaxa®, Boehringer Ingelheim International) 
(group 2). patients were enrolled in each group according 
to our weekly altered medication supply: every odd week 
enoxaparin and every even week dabigatran was admin-
istered. Our study thus can be called a quasi-randomised 
study.
Non-steroidal anti-inflammatory drugs (NSAIDs) and 
aspirin were suspended one week prior to surgery. preop-
eratively, renal and hepatic function tests, activated partial 
thromboplastin time (ApTT), prothrombin time (pT) and 
international normalized ratio (INr) were determined. 
exclusion criteria included revision surgery, underlying 
renal and hepatic dysfunction, blood coagulation disor-
ders and anticoagulant intake (acenocoumarol, warfarin, 
clopidogrel).
Anticoagulants were administered according to orthopae-
dic guidelines [3, 4, 21, 24]. In group 1, 40 mg enoxaparin 
was given subcutaneously 12 h before operation and at 8 p.m. 
for the next 28–35 days postoperatively. In group 2, 220 mg 
dabigatran etexilate was administered for patients below 
75 years of age and 150 mg over 75 years of age. Adminis-
tration was started 4 h postoperatively with a half dose (110 
or 75 mg) and then full dose was administered once a day at 
8 a.m. for 28–35 days after replacement [3–5, 16].
Surgeries were carried out under general, regional or 
combined general and regional anaesthesia, depending on 
what technique was felt most appropriate for the individual 
patient by the anaesthetic team. All operations were per-
formed by seven consultant orthopaedic surgeons working 
in a single orthopaedic department, using a direct lateral or 
Bauer’s approach. All patients received a cemented total 
hip prosthesis. Operations were performed without cell 
saver or other retransfusion systems. cefuroxime or clin-
damycin were used as perioperative antibiotic prophylaxis. 
Two closed suction drains were used for 24 h postopera-
tively. Drainage was collected in scaled bottles. The wound 
and drain site was covered with Mepore®-type bandages 
after drain removal.
paracetamol, tramadol and metamizole were adminis-
tered as pain relief as were required. physiotherapy started 
on the first postoperative day, fully weight bearing, with 
limitation of adduction and external rotation.
Minor bleeding events and major and clinically signifi-
cant bleedings were recorded according to previous pub-
lications and guidelines [1, 12]. Thrombotic events were 
recorded when clinical signs emerged.
Thrombosis and thromboembolism
Suspicion of thrombosis was established clinically. If 
swelling, excessive oedema, discolouration of the limb or 
a positive Mayer’s or homans’ sign were observed, col-
our duplex sonography of the limb was performed. After 
3 months, patients were phoned and asked whether they 
had been diagnosed or treated with deep vein thrombosis 
(DVT) or pulmonary embolism (pe) in another hospital. 
In case of clinical suspicion of pulmonary artery embolism 
(pAe), a computed tomography of the chest was performed 
according to our current protocol.
Major and clinically significant bleeding events
Major bleeding was defined as fatal bleeding; overt bleeding 
associated with ≥20 g/L fall in haemoglobin; overt bleed-
ing leading to transfusion of ≥2 units packed cells or whole 
blood; retroperitoneal, intracranial, intraocular or intraspinal 
bleeding; bleeding warranting treatment cessation or lead-
ing to reoperation. clinically significant bleeding events 
were defined as spontaneous skin haematoma ≥25 cm2, 
wound haematoma ≥100 cm2, spontaneous nose or gingi-
val bleeding >5 min, spontaneous or intervention-associated 
macroscopic haematuria lasting >24 h, and any other bleed-
ing event considered clinically significant [12–14].
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The calculated perioperative blood loss (V, mL) was 
compared between the two groups. For this purpose, the 
patient’s height (h, cm), weight (g, kg), preoperative 
haematocrit (hct0) and haematocrit on the first postopera-
tive day (hct1) were recorded. patients, who got transfusion 
in the first 24 h after the operation, were excluded from this 
calculation. Nadler’s formula was used for calculating the 
perioperative blood loss [36]:
V = eBV × ln(hct0/hct1)
estimated blood volumes (eBV) were calculated with 
the following formula:
eBV = A × h0,725 x g0,425− B
where A = 0.0236 for men; A = 0.0248 for women; 
B = 1.229 for men; B = 1.954 for women.
Minor bleeding events
Minor bleeding was defined as wound bleeding, serous 
wound discharge classified in four categories and wound 
haematoma smaller than 100 cm2 (Tables 1, 2).
Wound bleeding and serous wound discharge
Wound bleeding was defined as bleeding of the surgical 
wound into the dressing in the first postoperative 24 h, 
until drain removal. Its intensity was categorized accord-
ing to Table 1. Serous wound discharge was defined as 
the oozing of the surgical wound and drain site after 
drain removal. Discharge was examined every day. The 
duration in days and intensity of serous wound discharge 
were observed and recorded. The exact amount was doc-
umented on the third and seventh postoperative days, 
when wound dressings were followed up above the surgi-
cal and drain site, and examined and documented accord-
ing to the established categories (Table 1). The cessation 
of the serous ooze was precisely documented after the 
surgical intervention. Subgroup analysis was performed 
regarding the last patient on each particular list, to assess 
whether the shorter period between the completion of 
surgery and the next dose of anticoagulant would influ-
ence wound discharge/drainage.
Haematoma
The area of haematoma (blood suffusion) on the skin sur-
face was measured and patients were referred according to 
our established categories (Table 2).
Change in thigh volume
excessive oozing may not only present with discharge but 
also with increased thigh volume after Thr [19]. Jones and 
pearson developed an anthropometric method for correct 
estimation of leg volume by partitioning the volume of the 
leg into six segments which are similar to truncated cones 
[31]. Three segments’ data were sufficient to measure 
for calculating the thigh volume. Briefly, with the patient 
standing erect and the feet slightly apart, four circumfer-
ences were taken with a metric tape at predetermined 
sites: the gluteal furrow, one-third of the subischial height 
up from the tibial–femoral joint space, the minimum cir-
cumference above the knee, the maximum circumference 
around the knee. The heights above the floor level for each 
circumference were measured by stadiometer [40]. Thigh 
volume (ml) was then calculated by summing up the vol-
umes of three truncated cones. All equations were previ-
ously entered into the Microsoft excel software for faster 
results (Microsoft™, 2007).
Statistics
Data are shown as mean ± standard deviation (SD). Sta-
tistical analysis was done using t test, Chi-square test and 
ANOVA using StatSoft® Statistica v.9 statistical software. A 
p value of <0.05 was considered significant.
Results
122 patients were enrolled, 61 into each group. The number 
and descriptive data of the patients are presented in Table 3. 
Table 1  categories of wound 
bleeding (postoperative 0–24 h) 
and serous wound discharge 
(after drain removal)
0 clean and dry wound dressing
1 Small spots but not wet through
2 A part of the wound dressing wet through during a day
3 The dressing wet through fully during a day, change and covering gauze were necessary
Table 2  categories of haematoma
0 None (cm2)
1 <100
2 100–200
3 200–300
4 300–400
5 400–500
6 >500
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characteristics of patients were similar, without any signifi-
cant differences.
No patients developed clinical features of DVT dur-
ing the treatment and follow-up period, therefore duplex 
sonography was not performed. No pAe events or deaths 
occurred during the hospitalization and 3 months after the 
operation.
There were no significant differences between the two 
groups in major bleeding events (Table 4). 22 patients in 
the dabigatran group and 21 patients in the enoxaparin 
group needed transfusion in the postoperative period.
No significant differences were found between the two 
groups in volume of blood loss during surgery: 300 ml 
(±137.23) in dabigatran group and 314 ml (±197.32) in 
the enoxaparin group was measured. Volume of the postop-
erative drainage also did not differ significantly: 470.82 ml 
(±276.85) in dabigatran group and 471.64 ml (±253.3) 
in enoxaparin group was found. There were no signifi-
cant differences in perioperative calculated blood loss, 
which were 1,072.4 ml (±586.6) in the dabigatran group 
and 1,152.3 ml (±486) in the enoxaparin group. Subgroup 
analysis did not show any significant differences in wound 
bleeding/discharging and drainage volume regarding to 
patient’s position on the operation schedule (first or last on 
the list). No significant differences were found in the total 
blood loss as calculated by a total drop in preoperative and 
postoperative first day haemoglobin level: 30.7 g/L (±13.5) 
using dabigatran and 28.3 g/L (±12.7) using enoxaparin. 
eight patients from the enoxaparin group and three patients 
from the dabigatran group received transfusion in the first 
24 h after their operations, therefore they were excluded 
from this calculation and comparison of postoperative hae-
moglobin drops.
Wound bleeding also did not show significant differ-
ences between the two groups (Table 5).
Data on haematoma frequency are presented in Table 6. 
There was no statistical significance between groups.
Significant increases of thigh volumes were observed in 
both groups on the seventh postoperative day compared to 
preoperative volumes, however, no significant difference 
was found between the two groups (Fig. 1).
In contrast to these, the main differences between the 
two groups are in the duration and intensity of serous 
wound discharge. Duration of wound discharge was 2.2 
(±2.7) days in the dabigatran group and 1.2 (±1.9) days 
in the enoxaparin group after drain removal (p < 0.05) 
(Fig. 2). Significantly, higher intensity of wound drain-
ing was found in the dabigatran group (p < 0.05) (Table 7; 
Fig. 3).
Table 3  patient 
characteristics ± SD (min–max) enoxaparin Dabigatran
Number of patients 61 61
gender 16♂/45♀ 17♂/44♀
Average age 69 ± 9.7 (47–85) 69 ± 7.6 (52–86)
height (cm) 164 ± 8.9 (150–189) 164 ± 8.0 (148–186)
Weight (kg) 77 ± 14.1 (45–100) 76 ± 11.6 (48–99)
BMI (kg/m2) 28.5 ± 4.8 (19.1–37.7) 28.3 ± 4.3 (17.9–40.9)
estimated blood volume (mL) 4,464 ± 743.8 (2,775–6,241) 4,458 ± 637.9 (2,859–5,893)
haematocrit before surgery 0.40 ± 0.038 (0.30–0.50) 0.40 ± 0.038 (0.31–0.50)
haemoglobin before surgery (g/L) 134.7 ± 15.7 (94–176) 135.9 ± 13.5 (101–172)
Duration of surgery (min) 77 ± 18.8 (50–140) 74 ± 15.8 (50–120)
Anaesthesia general/regional/combination 16/38/7 16/37/8
Table 4  Significant bleeding complication in our study according to guidelines of previous publications
Data are shown as number of events, percentage in brackets (%)
enoxaparin (n = 61) Dabigatran (n = 61)
clinically overt bleeding leading to transfusion of ≥2 units packed cells 4 (6.6) 5 (8.2)
Wound haematoma ≥100 cm2 29 (47.5) 33 (54.1)
Intervention-associated macroscopic haematuria lasting >24 h 0 (0.0) 1 (1.6)
Table 5  Wound bleeding incidences in the two groups
Data are shown as number of events, percentage in brackets (%). Def-
initions of categories are found in Table 1
category 0 1 2 3
enoxaparin (n = 61) 2 (3.3) 24 (39.3) 16 (26.2) 19 (31.2)
Dabigatran (n = 61) 1 (1.6) 23 (37.7) 18 (29.5) 19 (31.2)
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Discussion
patients undergoing Thr are under increased risk for post-
operative DVT and VTe events [15, 26, 30], with up to 
42–60 % having an asymptomatic venographically proven 
DVT and 16–32 % having a pe in the absence of any 
thromboprophylactic measures [7].
Despite decades of clinical experience and a plethora of 
studies, the ideal method of VTe prophylaxis remains con-
troversial. chemical thromboprophylaxis mainly reduces 
risk of asymptomatic DVT and only marginally pe, but 
does not reduce fatal VTe and death rate [44].
In 2012 [24], the American college of chest physi-
cians (Accp) and the American Academy of Orthopaedic 
Surgeons (AAOS) suggested using either LMWh, fonda-
parinux, apixaban, dabigatran, rivaroxaban, LDuh, ace-
tylsalicylic acid, adjusted-dose VKA (all grade 1B) or 
an intermittent pneumatic device (grade 1c) after Thr. 
even prior to this, LMWhs have become standard throm-
boprophylactic drugs [42]. enoxaparin, is one of the most 
favoured subcutaneously administered antithrombotic 
agent in europe, was used as comparator during clinical 
trials with dabigatran etexilate. Trials with the new direct 
thrombin inhibitor investigated the major and clinically 
significant bleedings as safety endpoints, however, minor 
bleeding events were mostly ignored and their exact details 
were unknown [11–14]. Table 8 shows collected bleeding 
complications of the relevant doses in the studies with dabi-
gatran etexilate.
The BISTrO I determined the safe therapeutic range 
of dabigatran etexilate following Thr [11]. At the end of 
this study, the lack of any major bleeding episodes and 
potentially higher number of minor bleeding events were 
explained by inaccurately defined bleeding complication 
criteria.
Different doses of dabigatran were compared during 
BISTrO II study [12]. The higher doses of dabigatran were 
significantly more effective than enoxaparin, although also 
resulted in increased bleeding events.
re-NOVATe study declared that the 150 or 220 mg 
doses of dabigatran etexilate are as effective as 40 mg 
enoxaparin for the prevention of venous thromboembolism, 
with similar safety profile [14].
re-NOVATe II study found similar risk of bleeding and 
safety profiles in 220 mg dabigatran etexilate and 40 mg 
enoxaparin groups after Thr [13]. Minor and clinically 
relevant non-major bleeding was firstly mentioned, as sum-
marized results, which showed raised incidence of minor 
wound complications using dabigatran etexilate.
Table 6  haematoma frequency
Data are shown as number of events, percentage in brackets (%). Definitions of categories are found in Table 2
category 0 1 2 3 4 5 6
enoxaparin (n = 61) 23 (37.7) 9 (14.8) 6 (9.8) 10 (16.4) 4 (6.6) 2 (3.3) 7 (11.4)
Dabigatran (n = 61) 22 (36.1) 6 (9.8) 15 (24.6) 6 (9.8) 5 (8.2) 5 (8.2) 2 (3.3)
Fig. 1  postoperative thigh volume increase. Significant increases 
(hash) of thigh volumes on the seventh postoperative day were found 
in both groups compared to preoperative volumes, however, no sig-
nificant difference was found between the two groups (p < 0.05)
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Fig. 2  Duration of drain wound oozing. Duration of drain wound 
oozing in days. Asterisk means significant difference between the 
two groups (p < 0.05). Duration of serous wound discharge was 
2.2 (±2.7) days in the dabigatran group and 1.2 (±1.9) days in the 
enoxaparin group
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According to current guidelines, the recommended VTe 
prophylaxis duration is 28–35 days after Thr [3, 4, 16, 
24].
enoxaparin exhibits predictable anticoagulation and 
can be given at fixed doses, but subcutaneous administra-
tion limits its use in the outpatient setting. Disadvantages 
include an indirect method of action, risk of heparin-
induced thrombocytopenia (hIT), allergic reactions due 
to its animal origin and short elimination half-life [27]. In 
case of need, there is ability to monitor the thrombocyte 
count, the efficacy (ApTT) and administer protamine sul-
phate as antidote [16, 25].
Dabigatran etexilate is just as effective and safe as 
LMWhs, furthermore, it does not have the above-men-
tioned disadvantages. however, it lacks the option to be 
monitored or reversed. [16, 25].
Our clinical experiences with elevated serous wound 
discharge prodded us to explore the background of devel-
opment of dabigatran focusing on minor bleeding events 
and design a study to prove our observations. No previous 
similar detailed reports are available with dabigatran on the 
minor, but clinically important, side-effects of haematoma 
around operated area, oozing from the wound and pro-
longed discharge from the drain site. A previous study in 
the united Kingdom found significantly more delayed 
wound discharges after taking dabigatran postoperatively. 
Based on their study, they no longer prescribe dabigatran 
from the day of surgery but prefer to prescribe dalteparin 
until the wound is dry postoperatively and then discharge 
the patient home on oral dabigatran [22].
In our study, the incidence of major and clinically sig-
nificant bleeding events was higher in both groups com-
pared to dabigatran development trials [11–14], although 
the same previous guidelines were considered. patients 
were equally divided and operated by seven experienced 
orthopaedic surgeons using the same surgical technique. 
No significant differences were seen in terms of individual 
complication rates of surgeons.
Although our study involved a relatively small number 
of patients, we have managed to find significant differences 
in serous wound discharge. however, no such differences 
were found in terms of skin haematoma formation. There 
is currently no study that examined the long-term wound 
complication rate using dabigatran, however, there are pub-
lications which found elevated incidence of bleeding com-
plications and wound infection taking rivaroxaban [29]. 
Our aim was not to establish the pharmacological explana-
tion of minor bleeding complications. We can hypothetise 
that the earlier postoperative administration of these new 
oral anticoagulants might be responsible for the increased 
incidence of postoperative wound ooze.
A significant increase in thigh volume was found in our 
study in both groups between the initial and postoperative 
seventh day data, however, no significant differences were 
found between the two groups. Although our study involved 
a relatively small number of patients, we still found signifi-
cant differences in serous wound discharge rates. There are 
currently no studies on increased infection rates with dabi-
gatran etexilate, but a higher incidence of bleeding compli-
cations and importantly also wound infection was reported 
for rivaroxaban [29]. We can only hypothesise that the (too) 
early postoperative administration of these new oral antico-
agulants might be responsible for the increased incidence 
of postoperative wound ooze. The current Accp guidelines 
recommend to start LMWh as thromboprophylaxis after 
12 h or even later postoperatively rather than within 4 h or 
Table 7  Number of patients with different categories of serous wound discharge
Data are shown as number of events, percentage in brackets (%). Definitions of categories are found in Table 1
Day 3 Day 7
category All 1 2 3 All 1 2 3
enoxaparin (n = 61) 13 (21.3) 5 (8.2) 2 (3.3) 6 (9.8) 3 (4.9) 2 (3.3) 0 (0) 1 (1.6)
Dabigatran (n = 61) 23 (37.7) 7 (11.4) 2 (3.3) 14 (23.0) 10 (16.4) 3 (4.9) 3 (4.9) 4 (6.6)
Fig. 3  Intensity of serous wound discharge. (Asterisk) significantly 
higher serous wound discharge was found in the dabigatran group 
on the third and seventh postoperative days. Hash means significant 
decrease in serous wound discharge was measured in both groups 
between third and seventh postoperative days
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less preoperatively or 4 h or less postoperatively as recom-
mended by the manufacturer [16, 24].
An early study in 1981 mentioned anticoagulant ther-
apy causing wound haematoma and wound draining as 
risk factor of deep infection after Thr [6]. It is contro-
versial whether a discharging wound can be an important 
source of late periprosthetic infection [6, 17], however, 
some authors observed positive correlation between dis-
charge from the wound and late deep infection [18, 45]. 
The first report on minor, but clinically important side-
effects found an increased incidence of bruising and pro-
longed discharge from drain site after enoxaparin com-
pared to control group without thromboprophylaxis [43]. 
The “clexane-knee” entity was well known over the early 
introduction period of enoxaparin. Minor bleeding com-
plications caused reluctance in the use of LMWhs at that 
time [20]. A questionnaire study of hip and knee surgeons 
found in 1997 that 48 % of surgeons had stopped using 
LMWhs because of bruising, ooze, bleeding problems 
and formation of haematoma [33]. Over the last two dec-
ades, we have come to accept the minor side-effects of 
enoxaparin. The new dabigatran etexilate can potentially 
cause more prolonged oozing from the drain site and an 
increased incidence of serous wound discharge, which 
might prevent this agent from being widely used in ortho-
paedic surgery.
It is potentially unsafe to discharge a patient with an 
oozing wound or drain site, even when his/her postopera-
tive state would otherwise allow this, which might lead to 
longer hospitalization and prolonged antibiotic prophy-
laxis. This could potentially lead to increased costs [8, 9].
Our study has several strengths and weaknesses. It was 
performed in single large volume tertiary referral university 
department, using consecutive patients, and a standardized 
surgical technique. The two compared groups were found 
to be demographically identical. perioperative blood loss 
was monitored comprehensively (theatre, drain, haemoglo-
bin concentration, wound haematoma, drainage, serous dis-
charge). Arguably, our patient population is still relatively 
small, as establishing differences in reoperation or infec-
tion rate requires large multi-centre studies. We did use 
drains in primary Thr patients, which is although not an 
unheard technique, but relatively less common today [32, 
39]. We felt that this was not relevant regarding the aim 
of our study, as drain usage was universal, affecting both 
groups equally. The use of suction drains remains contro-
versial after joint arthroplasty. There is increasing evidence 
suggesting that drains are not routinely required as they do 
not have any positive effect [34, 37, 41].
Increased incidence of prolonged discharge from the 
drain site and the increased incidence of elevated serous 
wound discharge were found using dabigatran etexilate. 
Table 8  comparable bleeding events during the treatment periods of each study
Data are n (%)
Bid, twice daily; qd, once daily; n.a., means not applicable
a
 For all bleeding outcomes, none of the differences between each dabigatran etexilate dose and enoxaparin were significant
b
 Starting with a half dose 1–4 h postoperatively
c
 Starting the evening before surgery
Studies Total population Major bleeding events (%) clinically significant bleeding 
events (%)
Minor bleeding 
events (%)
BISTRO I
Dabigatran 50 mg bid 30 0 n.a. 2 (7.4)
Dabigatran 150 mg bid 29 0 n.a. 26 (89.7)
Dabigatran 300 mg qd 46 0 n.a. 41 (89.1)
BISTRO II
Dabigatran 50 mg bid 265 0 5 (1.9) 11 (4.2)
Dabigatran 150 mg bid 266 10 (3.8) 11 (4.1) 23 (8.6)
Dabigatran 300 mg bid 258 12 (4.7) 12 (4.7) 22 (8.5)
enoxaparin 40 mg qd c 270 6 (2.2) 7 (2.6) 14 (5.2)
RE-NOVATE
Dabigatran 220 mg qda,b 1,146 23 (2.0) 48 (4.2) 70 (6.1)
Dabigatran 150 mg qda,b 1,163 15 (1.3) 55 (4.7) 72 (6.2)
enoxaparin 40 mg qdc 1,154 18 (1.6) 40 (3.5) 74 (6.4)
RE-NOVATE II
Dabigatran 220 mg qdab 1,010 14 (1.4) 23 (2.3) 61 (6.0)
enoxaparin 40 mg qdc 1,003 9 (0.9) 20 (2.0) 54 (5.4)
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Further, large-scale multi-center studies could help estab-
lish the clinical relevance and effect on outcome of bleeding 
complications and more importantly potentially increased 
rates of infection associated with dabigatran use.
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